Samsung Pharmaceutical Files Phase 3 Clinical Trial Plan for PSP Drug GV1001, Statistical Success Rate of 10%
Samsung Pharmaceutical has submitted a Phase 3 clinical trial plan for GV1001 to treat progressive supranuclear palsy Richardson's syndrome to the Korean MFDS.
The trial will enroll 204 patients in a double-blind placebo-controlled design over 48 weeks, with a total duration of approximately 33 months.
The statistical probability of final drug approval is approximately 10%, indicating significant investment risk.
The company plans to apply for marketing authorization based on the trial results and proceed with commercialization if approved.
[AI Summary]Samsung Pharmaceutical filed a Phase 3 IND for GV1001 in PSP with a 10% statistical success rate, limiting short-term stock impact and requiring investors to monitor trial outcomes and potential capital needs.
KOSPI Filing Information
Major Management Matters Related To Investment Decision (Submission Of Protocol For Domestic Phase 3 Clinical Trial Of GV1001 For Progressive Supranuclear Palsy)